Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals has been acquired by Eli Lilly and Company in a transaction valued at $38.00 per share plus contingent value rights.

Centessa Pharmaceuticals announced the expiration of the HSR Act waiting period, marking a key milestone in its acquisition by Eli Lilly.

Eli Lilly and Company will acquire Centessa Pharmaceuticals plc for an upfront cash payment of $38.00 per share, with additional contingent value rights totaling up to $9.00 per share.

Centessa Pharmaceuticals PLC has finalized separation and advisory terms with former CEO Saurabh Saha, including equity vesting, a target bonus, and an advisory role.

Centessa Pharmaceuticals plc has filed an amendment detailing the employment agreement for its new Chief Executive Officer, Dr. Mario Alberto Accardi, effective January 1, 2026.

Centessa Pharmaceuticals announces a strategic leadership transition, appointing Dr. Mario Alberto Accardi as CEO to advance its pure-play orexin portfolio into multiple neuroscience indications.

Centessa Pharmaceuticals plc has entered into a definitive agreement to be acquired by Eli Lilly and Company for $38.00 per share in cash, plus a contingent value right.

Centessa Pharmaceuticals reported a widened net loss in Q3 2025 as increased R&D spending fueled progress in its OX2R agonist pipeline, including positive ORX750 and ORX142 clinical data.

Centessa Pharmaceuticals reported a reduced net loss and extended its cash runway into mid-2027, driven by strategic focus on its OX2R agonist program and a new licensing agreement with Genmab.

Centessa Pharmaceuticals announces its Q1 2025 financial results, highlighting a license agreement with Genmab and progress in its orexin agonist program.

Centessa Pharmaceuticals filed an amendment to its Q3 2024 report to include disclosures of Rule 10b5-1 trading plans adopted by certain officers.

Centessa Pharmaceuticals reports its third quarter 2024 results, highlighting a strategic shift to prioritize its Orexin program and discontinuing the SerpinPC program.

Centessa Pharmaceuticals' 2024 10-K filing details the company's financial status, pipeline advancements, and strategic shifts, focusing on its orexin agonist program and LockBody technology platform.

Centessa Pharmaceuticals' 2023 annual report details financial results, pipeline advancements, and strategic shifts, including progress in hemophilia and sleep disorder programs.

Medicxi Ventures Management and affiliated entities report changes in beneficial ownership following the acquisition of Centessa Pharmaceuticals plc by Eli Lilly and Company.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders set to receive cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company is finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Centessa Pharmaceuticals PLC has issued a proxy statement for its 2026 Annual General Meeting, scheduled for June 12, 2026, detailing proposals for director re-appointments, auditor ratification, and adoption of financial reports.

Centessa Pharmaceuticals PLC announced its 2024 annual results, highlighting significant progress in its orexin receptor 2 (OX2R) agonist pipeline, an extended cash runway into 2027, and a new licensing deal, alongside strategic discontinuations of other development programs.

Centessa Pharmaceuticals is holding its Annual General Meeting on June 20, 2025, seeking shareholder approval for director re-elections, auditor appointments, and remuneration policies.

Centessa Pharmaceuticals PLC highlights advancements in its pipeline programs, including SerpinPC and ORX750, while reporting its financial results for the year ended December 31, 2023.

Centessa Pharmaceuticals announces its 2024 Annual General Meeting (AGM) to be held on June 25, 2024, in London, detailing resolutions for shareholder voting including director re-appointments, auditor ratification, and share allotment authorizations.

Farallon Capital Management and associated individuals have reported the disposal of their entire stake in Centessa Pharmaceuticals following its acquisition by Eli Lilly.

Farallon Capital Management has filed a Schedule 13D reporting a 6.1% beneficial ownership stake in Centessa Pharmaceuticals plc.

General Atlantic and its affiliated entities have filed an exit amendment to their Schedule 13D, reporting their beneficial ownership in Centessa Pharmaceuticals plc has fallen below 5% after recent open market sales.

General Atlantic entities have filed an amended Schedule 13D, disclosing a plan to sell up to 3.5 million Centessa Pharmaceuticals ADSs.

Multiple Medicxi entities have filed a Schedule 13G amendment, reporting 0.0% beneficial ownership of Centessa Pharmaceuticals plc ordinary shares as of June 30, 2026.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 1,800 shares of Centessa Pharmaceuticals PLC common stock as of June 30, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 7.39% of Centessa Pharmaceuticals plc's ordinary shares.

Adage Capital Management, L.P. and its associated individuals have reported beneficial ownership of 5.77% of Centessa Pharmaceuticals plc's ordinary shares as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 7.5% of Centessa Pharmaceuticals PLC's common stock as of March 31, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 9.97% beneficial ownership stake in Centessa Pharmaceuticals plc, holding 14,555,555 ordinary shares.